NCT07285174

Brief Summary

The aim of this study is to prospectively collect clinical information on patients with lymphoma, and to explore the best therapeutic strategies in the real-world population.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
44mo left

Started Dec 2025

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Dec 2025Dec 2029

First Submitted

Initial submission to the registry

December 3, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 16, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

December 18, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

2 years

First QC Date

December 3, 2025

Last Update Submit

December 3, 2025

Conditions

LymphomaCohort

Keywords

LymphomaClinicalCohort

Outcome Measures

Primary Outcomes (1)

  • Progression Free Survival (PFS)

    Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.

    Baseline up to data cut-off (up to approximately 1 year)

Secondary Outcomes (1)

  • Overall Survival (OS)

    Baseline up to data cut-off (up to approximately 1 year)

Study Arms (1)

Shanghai Lymphoma Clinical Cohort

Shanghai Lymphoma Clinical Cohort

Other: No interventions need to be specified for this study

Interventions

No interventions need to be specified for this studyOTHER

No interventions need to be specified for this study

Shanghai Lymphoma Clinical Cohort

Eligibility Criteria

Age16 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult patients with histologically confirmed diagnosis of non-Hodgkin lymphoma.

You may qualify if:

  • Age ≥ 16 years (including 16 years old).
  • Patients newly diagnosed with non-Hodgkin lymphoma
  • Patients who have received systematic clinical treatment.
  • Patients with measurable lesions, at least containing one effective evaluation of efficacy.

You may not qualify if:

  • Patients who only receive supportive treatment.
  • Patients who cannot obtain effective evaluation data of efficacy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

DNA and RNA will be retained.

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Weili Zhao, MD, PhD

CONTACT

+862164370045zwl_trial@163.com

Pengpeng Xu, MD

CONTACT

+862164370045pengpeng_xu@126.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dean

Study Record Dates

First Submitted

December 3, 2025

First Posted

December 16, 2025

Study Start

December 18, 2025

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2029

Last Updated

December 16, 2025

Record last verified: 2025-12